Medtronic PLC

Medtronic PLC(MDT)股票分析

$94.230

+1.234 (+1.31%)收盘时

Loading chart…
最高
94.720
开盘
93.010
成交量加权均价
93.70
成交量
49.86M
市值
101.72B
最低
92.160
成交额
4.67B
企业价值/息税折旧摊销前利润(TTM)
13.65

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

AI 分析 of Medtronic PLC (MDT)

买入

Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.

分析师评级(23)

上行空间 +18.60%
持有
11 买入
12 持有
0 卖出
当前: 94.23
最低
102.00
平均
111.76
最高
120.00

BTIG

2026-10-12

目标价

$99

买入

Barclays

2026-10-06

目标价

$95

Equal Weight

Deutsche Bank

2026-09-03

目标价

$92

持有

UBS

2026-09-03

目标价

$110

买入

Mizuho

2026-09-02

目标价

$115

跑赢大盘

估值指标

Medtronic PLC(MDT)当前预期市盈率为 14.93,5 年平均预期市盈率为 16.06。

预期市盈率

合理
5 年均值 P/E
16.06
当前P/E
14.93
高估
17.75
低估
14.37

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.65
当前EV/EBITDA
13.65
高估
15.00
低估
12.31

预期市销率

合理
5 年均值 P/S
3.43
当前P/S
2.95
高估
3.92
低估
2.94

Alphio AI 对 MDT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MDT

$89.49

情景价格

基

基准

基准 · 50%MDT

$72.02

情景价格

悲

悲观

悲观 · 25%MDT

$70.55

情景价格

持有 MDT 的大户

R

Renaissance Technologies Corp.

+ 持有MDT

+15.22%

3个月收益率

E

Edmond de Rothschild Asset Management (France)

+ 持有MDT

+8.72%

3个月收益率

S

Squarepoint OPS LLC

+ 持有MDT

+8.30%

3个月收益率

L

LGT Fund Management Company AG

+ 持有MDT

+8.05%

3个月收益率

A

Arrowstreet Capital, Limited Partnership

+ 持有MDT

+7.99%

3个月收益率

G

GuideStone Capital Management, LLC

+ 持有MDT

+7.56%

3个月收益率

事件时间线

2026-10-13 (ET)

16:00:00

Medtronic Shares Up 0.51% to $92.39

2026-10-12 (ET)

10:00:00

Notable Stock Gains for Medtronic and Others

09:00:00

Medtronic Announces Oversubscribed MiniMed Stock Exchange

2026-10-01 (ET)

16:30:00

AMA Approves New CPT Codes for Medtronic

2026-09-30 (ET)

09:30:00

Medtronic Achieves Regulatory Milestones for Cardiac Ablation Software

资讯

MDT 常见问题 —— 由 Alphio AI 解答

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易